Alt Üriner Sistem Semptomları ve Anksiyete Arasındaki İlişki

Objective & Hypothesis:Aim: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are prevalent and interfere with the quality of life (QoL) of older men.

📊

Key Findings & Data:According to observaıtional, 22.6% of LUTS/BPH patients reported anxiety or depression.

💡

Conclusion & Impact:Patients according to Qmax were divided into two groups as moderate (group 3, Qmax >9) and severe (group 4, Qmax

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Aim: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are prevalent and interfere with the quality of life (QoL) of older men. According to observaıtional, 22.6% of LUTS/BPH patients reported anxiety or depression. The aim of our study was to investigate the potential influences of anxiety and QoL to LUTS/BPH. Material and Method: We examined consecutive 42 patients admitted to our outpatient clinic with LUTS at Bor State Hospital. We examined and recorded maximum urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS) also Hamilton anxiety rating scale for anxiety and IPSS QoL were utilized in the study. Patients according to IPSS were divided into two groups as moderate (group 1, IPSS 19) LUTS. Patients according to Qmax were divided into two groups as moderate (group 3, Qmax >9) and severe (group 4, Qmax

Özet

Giriş: Benign prostat hiperplazisi'ne (BPH) sekonder gelişen alt üriner sistem semptomları (AÜSS) yaygın ve yaşlı erkeklerin yaşam kalitesini etkileyen bir durumdur. Araştırmacılara göre AÜSS/BPH hastalarının önemli bir oranında (% 22,6) anksiyete veya depresyon rapor edilmiştir. Gereç ve Yöntem: Bor Devlet Hastanesi üroloji polikliniğine AÜSS ile başvuran ardışık 42 hasta muayene edildi ve maximum idrar akım hızı (Qmax), Uluslararası Prostat Semptom Skoru (IPSS) sonuçları kaydedildi. Ayrıca hastalarda IPSS yaşam kalite endexi (QoL) ve anksiyete için Hamilton anksiyete değerlendirme ölçeği kullanıldı. Hastalar IPSS'ye göre iki gruba ayrıldı. Grup 1 orta (IPSS 19) AÜSS. Aynı şeklide hastalar Qmax'a göre iki gruba ayrıldı. Grup 3 orta (Qmax >9) ve grup 4 şiddetli (Qmax

🔖

Cite This Article

GUL, A. I., BAL, U., CEVIK, R., ATAR, M., ALBAYRAK, S., ZENGIN, K., TANIK, S. (2022). Alt Üriner Sistem Semptomları ve Anksiyete Arasındaki İlişki. Journal of Clinical and Analytical Medicine, Cilt: 7 - Sayı: 4, 430–433. https://ajindex.com/articles/560837

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (7)

Atılgan D, Yaşar A, Erdemir F, Parlaktaş BS, Uluocak N, Fırat F. Comparison the Efficacy of Four Different Alpha Blockers in the Treatment of Benign Prostaıtic Hyperplasia. J Clin Anal Med 2011;2(2):27-31.
Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden. EpiLUTS. BJU Int 2009;103(3):12-23.
Barry MJ, Cantor A, Roehrborn CG. Relationships among participant interna- tional prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. J Urol 2013;189(3):987-92.
Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol 2013;189(Suppl.1):S107-14. Berry SJ, Isaacs JT. Comparative aspects of prostatic growth and androgen me- tabolism with aging in the dog versus the rat. Endocrinology 1984;114(2):511-20.
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower uri- nary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46(5):547-54.
Gratzke C, Schlenker B, Weidlich P, Seitz M, Reich O, Stief CG. [Benign prostatic hyperplasia: background and diagnosis]. MMW Fortschr Med 2007;149(33-34):25 Badia X, Garcia-Losa M, Dal-Re R, Carballido J, Serra M. Validation of a harmo- nized Spanish version of the IPSS: evidence of equivalence with the original Ameri- can scale. International Prostate Symptom Score. Urology 1998;52(4):614-20. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int;97(Suppl.2):3-6;S21-2. Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression. EpiLUTS. BJU Int;103(Suppl.3):S4-11. Seyfried LS, Wallner LP, Sarma AV. Psychosocial predictors of lower uri- nary tract symptom bother in black men: the Flint Men's Health Study. J Urol;182(3):1072-7.
Kunit T, Lusuardi L. An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol 2014;6(6):67-70. Hamilton M. The assessment of anxiety states by rating. Br J Med P